Serina Therapeutics (FRA:2BO) ROCE %: -220.60% (As of Mar. 2026)


FRA:2BO Serina Therapeutics Inc FRA:2BO
19 GF Score
Price €1.48
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics ROCE %?

Serina Therapeutics FRA:2BO +8.03% 19 ROCE % is -220.60% as of Mar. 2026. GuruFocus rates FRA:2BO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Serina Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -220.60%.

Serina Therapeutics  (FRA:2BO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Serina Therapeutics ROCE % Related Terms

Serina Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics ROCE % Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-85.66 -295.94 145.88 -183.97 -459.65

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -434.54 -513.60 -403.46 -356.33 -220.60
FRA:2BO
19GF Score
Serina Therapeutics Inc FRA:2BO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics ROCE % Calculation

Serina Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-16.212/( ( (6.421 - 2.26) + (5.936 - 3.043) )/ 2 )
=-16.212/( (4.161+2.893)/ 2 )
=-16.212/3.527
=-459.65 %

Serina Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-23.188/( ( (5.936 - 3.043) + (23.614 - 5.484) )/ 2 )
=-23.188/( ( 2.893 + 18.13 )/ 2 )
=-23.188/10.5115
=-220.60 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -220.60% mean?
Serina Therapeutics (FRA:2BO) has a ROCE % of -220.60% as of Mar. 2026.
Is Serina Therapeutics' ROCE % too high?
Serina Therapeutics' current ROCE % is -220.60%. Overall, Serina Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' ROCE % compare to NRSN and IGC?
Serina Therapeutics' ROCE % of -220.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Serina Therapeutics's current ROCE % is -220.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (FRA:2BO) has a current ROCE % of -220.60%. The current ROCE % is -220.60%. Serina Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Serina Therapeutics (FRA:2BO), the current ROCE % is -220.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges SER:USA
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
19GF Score

Get the complete analysis for FRA:2BO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.48
Price